载脂蛋白M在炎症性肠病中的测定及意义

doi:10.3969/j.issn.1004-583X.2016.01.013

临床荟萃 ›› 2016, Vol. 31 ›› Issue (1): 53-55.doi: 10.3969/j.issn.1004-583X.2016.01.013

载脂蛋白M在炎症性肠病中的测定及意义

王婷婷, 汪良芝

苏州大学附属第三医院消化内科,江苏常州 213003

收稿日期:2015-08-28 出版日期:2016-01-05 发布日期:2016-04-19
通讯作者: 汪良芝,Email:wangdoc371@sohu.com
基金资助:
常州市科技局应用基础研究计划资助项目(CJ20112006)

Expression and clinical significance of apolipoprotein M in inflammatory bowel disease

Wang Tingting, Wang Liangzhi

Department of Gastroenterology, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China

Received:2015-08-28 Online:2016-01-05 Published:2016-04-19
Contact: Wang Liangzhi, Email: wangdoc371@sohu.com

摘要/Abstract

摘要： 目的探讨血清载脂蛋白M (apolipoprotein M,apoM)在炎症性肠病(inflammatory bowel disease,IBD)患者血清中的表达及意义。方法采用双抗夹心酶联免疫吸附法(enzyme-linked immuno sorbent assay,ELISA)检测101例IBD患者及69例健康对照组的血清apoM和肿瘤坏死因子a(tumor necrosis factor-a,TNF-α)水平,分析其与IBD疾病活动度的相关性。结果溃疡性结肠炎(ulcerative colitis,UC)组、克罗恩病(Crohn＇s disesse,CD)组和健康对照组的血清apoM水平分别为(13.5±8.8) mg/L,(10.2±5.8) mg/L和(2.0±1.3) mg/L,且UC组血清apoM水平高于CD组,差异有统计学意义(P＜0.05);UC和CD患者血清apoM水平均随着疾病活动度的增加而升高,各等级间差异有统计学意义(P＜0.05);IBD组血清apoM水平与血清TNF-α水平呈正相关(r=0.314,P=0.001),以CD组为著(r=0.365,P=0.010)。结论 UC、CD患者血清apoM水平与疾病活动度相关,在评估IBD疾病活动度上有潜在的运用价值。

关键词: 炎性肠疾病, 载脂蛋白M, 疾病活动度

Abstract: Objective To investigate the expression and clinical value of serum apolipoprotein M (apoM) in patients with inflammatory bowel disease (IBD).Methods The levels of serum apoM and TNF-α in 101 IBD patients and 69 healthy individuals were measured by ELISA.Results The serum concentration of apoM was respectively (13.5±8.8) mg/L, (10.2±5.8) mg/L and (2.0±1.3) mg/L in ulcerative colitis (UC) patients, Crohn disease (CD) patients and healthy controls, and the level of serum apoM in UC patients was significantly higher than that of CD patients (P<0.05). Serum apoM concentrations in both UC and CD patients were significantly elevated with increased disease activity(P<0.05). In addition, serum apoM concentration and TNF-α concentration were positively correlated in IBD group (r=0.314,P=0.001), especially in CD subgroup (r=0.365,P=0.010).Conclusion The levels of serum apoM in UC and CD patients were correlated with disease activity and have potential application value in evaluating disease activity of IBD.

Key words: inflammatory bowel diseases, apolipoprotein M, disease activity

中图分类号:

R574

王婷婷, 汪良芝. 载脂蛋白M在炎症性肠病中的测定及意义[J]. 临床荟萃, 2016, 31(1): 53-55.

Wang Tingting, Wang Liangzhi. Expression and clinical significance of apolipoprotein M in inflammatory bowel disease[J]. Clinical Focus, 2016, 31(1): 53-55.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.013

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/53

参考文献

[1] 徐萍, 徐东升, 祝荫, 等. 炎症性肠病病情活动监测指标的临床价值[J]. 临床荟萃, 2007, 22 (6): 385-388.
[2] 刘永爱, 徐之静, 汪良芝. 红细胞分布宽度与炎症性肠病活动度的关系[J]. 临床荟萃, 2013, 28 (1): 41-43.
[3] Kumaraswamy SB,Linder A, Akesson P, et al. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes[J]. Crit Care, 2012,16(2): R60.
[4] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年·广州) [J]. 中华内科杂志, 2012, 51 (10): 818-831.
[5] 黎照环, 胡敏. 人血清apom的ELISA检测方法评价[J]. 临床检验杂志, 2011, 29 (3): 168-170.
[6] Xu N, Dahlback B. A novel human apolipoprotein (apoM) [J]. J Biol Chem, 1999, 274 (44): 31286-31290.
[7] 刘茵茵, 胡敏. 载脂蛋白M的调控与脂代谢相关疾病[J]. 中华临床实验室管理电子杂志, 2014, 2 (2): 23-27.
[8] Ren K, Tang ZL, Jiang Y, et al. Apolipoprotein M[J]. Clin Chim Acta, 2015, 446: 21-29.
[9] Zhang XY, Dong X, Zheng L, et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization[J]. Acta Histochem, 2003, 105(1): 67-72.
[10] Faber K, Hvidberg V, Moestrup SK,et al. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M[J]. Mol Endocrinol, 2006, 20 (1): 212-218.
[11] Huang XS,Zhao SP, Hu M, et al. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation[J]. Med Hypotheses, 2007, 69 (1): 136-140.
[12] Gu JG, Zhu CL, Cheng DZ, et al. Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication[J]. Lipids Health Dis, 2011, 10: 154.
[13] 赵婷婷. 载脂蛋白M对细菌性肺炎的诊断和病情严重程度的判断价值[J]. 国际检验医学杂志, 2015,(5): 588-590.
[14] HJ Hu, EH Jin, SH Yim, et al. Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis[J]. Exp Mol Med, 2011, 43 (11): 613-621.
[15] Xu N, Zhang XY, Dong X, et al. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells[J]. Biochem Biophys Res Commun, 2002, 292(4): 944-950.
[16] Feingold KR, Shigenaga JK, Chui LG, et al. Infection and inflammation decrease apolipoprotein M expression[J]. Atherosclerosis, 2008, 199(1): 19-26.
[17] 郭伶霞, 王玲, 周后钢, 等. 细菌感染患者载脂蛋白M与感染程度的相关性研究[J]. 临床检验杂志, 2013,8: 575-578.
[18] 张道权, 吴正祥. 炎症性肠病的抗肿瘤坏死因子治疗安全评价[J]. 临床荟萃, 2007, 22 (2): 145-147.
[19] Gao JJ, Hu YW, Wang YC, et al. ApoM suppresses TNF-alpha-Induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-kappaB[J]. DNA Cell Biol, 2015,34(8):550-556.
[20] 刘洪尧, 梁云, 刘中华, 等. 载脂蛋白M对小鼠血清白细胞介素-10和白细胞介素-6的影响[J]. 中华实验外科杂志, 2015, 32 (4): 783.
[21] Blaho VA, Galvani S, Engelbrecht E,et al. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation[J]. Nature, 2015,523(7560):342-346.

载脂蛋白M在炎症性肠病中的测定及意义

Expression and clinical significance of apolipoprotein M in inflammatory bowel disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈晓天, 霍丽娟. 血清总胆红素水平在炎症性肠病中临床意义的meta分析[J]. 临床荟萃, 2023, 38(8): 677-685.
[2]	葛超毅, 王化虹. 炎症性肠病营养支持治疗进展[J]. 临床荟萃, 2018, 33(8): 650-655,660.
[3]	宋岩1，杨虎2，姜葵1，王邦茂1. 沙利度胺及其类似物治疗炎症性肠病的系统性回顾[J]. 临床荟萃, 2018, 33(5): 434-439.
[4]	李玥，钱家鸣. 炎症性肠病合并艰难梭菌感染的研究进展[J]. 临床荟萃, 2018, 33(5): 394-397.
[5]	李玥，钱家鸣. 免疫抑制剂在炎症性肠病治疗中的应用进展[J]. 临床荟萃, 2016, 31(8): 824-827.
[6]	郭金波，张晓岚. 5-氨基水杨酸在炎症性肠病中的合理应用[J]. 临床荟萃, 2016, 31(8): 820-823.
[7]	雷蕾1，2，张晓岚1，尹凤荣1. 机会性感染与炎症性肠病[J]. 临床荟萃, 2016, 31(8): 865-868.
[8]	牛巍巍，赵丹丹，霍晓霞. 幽门螺杆菌与炎症性肠病[J]. 临床荟萃, 2016, 31(8): 861-964.
[9]	迟雁. 肠道微生态与炎症性肠病[J]. 临床荟萃, 2016, 31(8): 857-860.
[10]	王冬，张晓岚. 内镜在炎症性肠病中的作用[J]. 临床荟萃, 2016, 31(8): 852-856.
[11]	李俊霞，田原，王化虹，刘新光. 重视炎症性肠病的皮肤表现[J]. 临床荟萃, 2016, 31(8): 847-851.
[12]	魏天桐，王化虹. 炎症性肠病患者的营养支持治疗[J]. 临床荟萃, 2016, 31(8): 834-837.
[13]	刘永爱;徐之静;汪良芝. 红细胞分布宽度与炎症性肠病活动度的关系[J]. 临床荟萃, 2013, 28(1): 41-43.
[14]	刘献民;牟方宏. Th17细胞在炎症性肠病中的作用及其临床价值[J]. 临床荟萃, 2010, 25(15): 1368-1369.
[15]	邢亚威;刘春玉;王媛. 与炎症性肠病病情活动相关的因素[J]. 临床荟萃, 2008, 23(20): 1519-1520.